The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer

• DOI: 10.1007/s13277-014-2151-2
• Publication Date: 2014-06-02T04:55:34Z
• Authors: S. Karabulut; F. Tas; D. Tastekin; M. Karabulut; C. T. Yasasever; R. Ciftci; M. Güveli; M. Fayda; S. Vatansever; M. Serilmez; R. Disci; A. Aydıner
• Keywords: VCAM-1

The purpose of this study was to determine the clinical significance vascular cell adhesion molecule-1 (VCAM-1) and epithelial molecule (EpCAM) in breast cancer (BC) patients. Ninety-six BC patients 30 age- sex-matched healthy controls were enrolled into study. Pretreatment serum markers determined by solid-phase sandwich (enzyme-linked immunosorbent assay (ELISA)). median age at diagnosis 48 years (range 29-80 years). Majority (71 %) had luminal subtype, 38.5 % metastatic disease. Twenty-nine (30 showed tumor progression, 20 (21 died during follow-up. Median progression-free survival (PFS) overall (OS) 8.6 ± 1.7 35.5 1.5 months, respectively. baseline EpCAM levels significantly higher than those (p < 0.001). There no significant difference VCAM-1 between = 0.47). No correlation detected other parameters > 0.05). Patients with HER-2-positive triple-negative tumors poorer PFS 0.04 p 0.001, respectively), while disease chemotherapy unresponsiveness adverse effect on OS analysis 0.001 respectively). Neither nor identified have a prognostic role either or (VCAM-1 0.76 0.32; 0.16 0.69, Even though any predictive could not be for both markers, found diagnostic value